The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Thomas CluzeauDuring the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Thomas Cluzeau, Centre Hospitalier Universitaire de Nice, Nice, FR. We asked: Is azacitidine + APR-246 safe and effective in patients with TP53 mutated MDS and acute myeloid leukemia?
Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?
Results from the phase II study, evaluating the novel p53-activating drug, APR-246, + azacitidine for the treatment of patients with TP53 mutated MDS and acute myeloid leukemia, were presented at this year's EHA meeting. The combination has demonstrated a manageable toxicity profile and promising clinical efficacy in this setting.